5Kotecha MT, Afghan RK, Vasilikopoulou E, et al. Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein : evidence for tumour - induced immune deviation[J]. Vaccine, 2003, 21: 2506.
6Kuhn L, Denny L, Pollack A, et al. Human papillomarvirus DNA testing for cervical screening in low - resource settings [J]. J Natl Cancer Inst, 2000, 92: 818.
7Herrero R, Hildesheim A, Bratti C, et al. Population - based study of human papillomavirus infection and cervical neoplasia in rural costa Rica[J]. J Natl Cancer Inst, 2002, 92: 464.
8Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of human papiUomavirus testing within a cervical screening programme [ J ]. Health Techcol Assess, 1999,3 ( 1 ) : 1.
9Deacon JM, Evans CD, Yule R, et al. Sexual behaviour smoking as determinants of cervical HPV infection and of CIN3 a- mong those infected : a case - control study nested within the Manchester cohort[J]. Br J Cancer, 2001, 88: 1565.
10Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial in HIV infected women [ J ]. JAMA, 2002, 283: 1031.
二级参考文献43
1司静懿，J Cancer Res Clin Oncol，1991年，117卷，460页
2蔡良琬，核酸研究技术.上，1989年
3Hess S, Smola H, Sandaradura DS. Loss of IL-6 receptor expression in cervical carcinoma cells inhibits autocrine IL-6 stimulation: abrogation of constitutive monocyte chemoattractant protein-1 production.J Immunol, 2000 , 165:1939-1948.
4van der Burg SH, de Jong A, Welters MJ, et al. The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res, 2002, 89:275-284.
5Jakob T, Ring J, Udey M. Multistep navigation of Langerhans/dendritic cells in and out of the skin. J Allergy Clin Immunol, 2001, 108:688-696.
6Fausch SC, Da Silva DM, Rudolf MP, et al. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol, 2002,169:3242-3249.
7Connor JP, Ferrer K, Kane JP, et al. Evaluation of Langerhans' cells in the cervical epithelium of women with cervical intraepithelial neoplasia. Gynecol Oncol, 1999, 75:130-135.
8Mota F, Rayment N, Chong S, et al. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol, 1999, 116:33-40.
9Bornstein J, Lahat N, Kinarty A, et al. Interferon-beta and -gamma, but not tumor necrosis factor-alpha, demonstrate immunoregulatory effects on carcinoma cell lines infected with human papillomavirus. Cancer, 1997,79:924-934.
10Adams M, Borysiewicz L, Fiander A, et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine, 2001, 19:2549-2556.
2Steben M, Duatrte FE. Human papillomavirus infection: epidemiology and pathophysiology E J：. Gynecologic Oncology, 2007,107 : $2 - 5.
3Tabora N, Frrera A, Bakkers JM,et al. High HPV16 viral load is associated with increased cervical dysplasia in Honduran women[J]. Am J Trop Med Hyg,2008,78( 5) :843 -846.
